These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38455420)

  • 1. Tumor-associated macrophages promoting PD-L1 expression in infiltrating B cells through the CXCL12/CXCR4 axis in human hepatocellular carcinoma.
    Lian SL; Lu YT; Lu YJ; Yao YL; Wang XL; Jiang RQ
    Am J Cancer Res; 2024; 14(2):832-853. PubMed ID: 38455420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12.
    Chen J; Feng W; Sun M; Huang W; Wang G; Chen X; Yin Y; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
    Gastroenterology; 2024 Jul; 167(2):264-280. PubMed ID: 38417530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer‑associated fibroblast‑induced M2‑polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor‑1 pathway.
    Chen S; Morine Y; Tokuda K; Yamada S; Saito Y; Nishi M; Ikemoto T; Shimada M
    Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34195849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress.
    Li Z; Duan D; Li L; Peng D; Ming Y; Ni R; Liu Y
    Front Pharmacol; 2024; 15():1382256. PubMed ID: 38957393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia.
    Semaan A; Dietrich D; Bergheim D; Dietrich J; Kalff JC; Branchi V; Matthaei H; Kristiansen G; Fischer HP; Goltz D
    Virchows Arch; 2017 Feb; 470(2):185-196. PubMed ID: 27913861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
    Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
    Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TREM2
    Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J
    J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GOLM1 exacerbates CD8
    Chen J; Lin Z; Liu L; Zhang R; Geng Y; Fan M; Zhu W; Lu M; Lu L; Jia H; Zhang J; Qin LX
    Signal Transduct Target Ther; 2021 Nov; 6(1):397. PubMed ID: 34795203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy.
    Sun G; Liu H; Zhao J; Zhang J; Huang T; Sun G; Zhao S; Zhang Z; Cao H; Rong D; Kong X; Ji Q; Liu L; Wang X; Tang W; Xia Y
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking MARCO
    Ding L; Qian J; Yu X; Wu Q; Mao J; Liu X; Wang Y; Guo D; Su R; Xie H; Yin S; Zhou L; Zheng S
    Cancer Lett; 2024 Feb; 582():216568. PubMed ID: 38065400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity.
    Guo S; Wang X; Zhou H; Gao Y; Wang P; Zhi H; Sun Y; Zhang Y; Gan J; Xiao Y; Ning S
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The XOR-IDH3α axis controls macrophage polarization in hepatocellular carcinoma.
    Lu Y; Sun Q; Guan Q; Zhang Z; He Q; He J; Ji Z; Tian W; Xu X; Liu Y; Yin Y; Zheng C; Lian S; Xu B; Wang P; Jiang R; Sun B
    J Hepatol; 2023 Nov; 79(5):1172-1184. PubMed ID: 37473847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nano formulated Resveratrol inhibits PD-L1 in oral cancer cells by deregulating the association between tumor associated macrophages and cancer associated fibroblasts through IL-6/JAK2/STAT3 signaling axis.
    Pradhan R; Paul S; Acharya SS; Sinha S; Dash SR; Kundu CN
    J Nutr Biochem; 2024 Mar; 125():109568. PubMed ID: 38185347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.
    Wu Q; Zhou W; Yin S; Zhou Y; Chen T; Qian J; Su R; Hong L; Lu H; Zhang F; Xie H; Zhou L; Zheng S
    Hepatology; 2019 Jul; 70(1):198-214. PubMed ID: 30810243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of M2 type macrophage-derived extracellular vesicles regulating PD-L1 expression via the MISP/IQGAP1 axis in hepatocellular carcinoma immunotherapy resistance.
    Wang X; Ye X; Chen Y; Lin J
    Int Immunopharmacol; 2023 Nov; 124(Pt A):110848. PubMed ID: 37633233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1
    Gok Yavuz B; Gunaydin G; Gedik ME; Kosemehmetoglu K; Karakoc D; Ozgur F; Guc D
    Sci Rep; 2019 Feb; 9(1):3172. PubMed ID: 30816272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.